The MIEF2 Knockout HeLa Cell Line is a CRISPR/Cas9-edited human cell line harboring targeted disruption of the MIEF2 gene, encoding mitochondrial elongation factor 2 (MiD49). This loss-of-function model enables precise investigation of mitochondrial outer membrane receptor function and downstream dynamin-related protein 1 (DRP1)-mediated mitochondrial fission in a well-characterized mammalian system. The knockout cell line is supplied as a standardized HeLa derivative, empowering researchers to dissect molecular mechanisms governing mitochondrial dynamics and apoptotic signaling without reliance on transient knockdown approaches.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma line derived from a patient with HPV-18 infection. These cells exhibit constitutive expression of the E6 and E7 viral oncoproteins, which inactivate the tumor suppressors p53 and pRB, respectively, thereby disrupting key cell cycle and apoptosis checkpoints. HeLa cells are extensively employed in cancer biology, drug discovery, and cell signaling studies due to their robust growth, genetic tractability, and well-characterized molecular landscape. This background provides a clinically relevant context for studying mitochondrial-mediated death pathways often dysregulated in malignancies.
MIEF2 encodes MiD49, a mitochondrial outer membrane receptor specifically recognizing DRP1, a dynamin-related GTPase. In the mitochondrial fission pathway, MIEF2 cooperates with interacting partners such as MIEF1, FIS1, and MFF to nucleate DRP1 recruitment. Upstream signals including AMPK-driven energy stress and apoptotic stimuli activate MIEF2, promoting DRP1 oligomerization and mitochondrial constriction. This triggers mitochondrial fragmentation, facilitating cytochrome c release and downstream caspase cascade activation. Consequently, MIEF2 serves as a signal-responsive mediator that couples cellular stress detection to mitochondrial remodelling and intrinsic apoptosis execution.
In the HeLa cell context, the MIEF2 knockout model is particularly significant because HPV-mediated inactivation of p53 and pRB profoundly alters apoptotic competence and mitochondrial dynamics. These alterations often contribute to chemoresistance and tumor cell survival. By eliminating MIEF2 function, researchers can specifically abrogate DRP1-dependent mitochondrial fission, enabling dissection of how fission regulates cytochrome c release and caspase-dependent apoptosis independently of other mitochondrial quality control pathways. This tool offers a powerful system to interrogate the interplay between mitochondrial morphology and cell death in a cancer model where apoptotic signaling is inherently compromised.
The MIEF2 Knockout HeLa Cell Line supports diverse experimental applications, including immunofluorescence-based assessment of mitochondrial morphology, mitochondrial fragmentation staining, and Western blotting for DRP1 and cytochrome c release during apoptosis induction. Co-immunoprecipitation experiments can map protein interactions with DRP1, MIEF1, or FIS1, while flow cytometry quantifies apoptosis. Metabolic flux analysis using Seahorse technology reveals bioenergetic consequences. This model is valuable for investigations into cancer metabolism, drug resistance, neurodegenerative disorders, and mitochondrial diseases. For additional information, please contact Ascent Research.
